Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Carcinoma, Renal Cell

ClinicalTrials.gov lists 1,949 trials for Carcinoma, Renal Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 116.

MeSH D002292 Neoplasms Neoplasm C04 C12 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 426 Phase 1/2 Phase 1/2 214 Phase 2 Phase 2 592 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 116 Phase 4 Phase 4 25 Not applicable Not applicable 225 Observational Observational 338 Phase 1 Phase 1 426 Phase 1/2 Phase 1/2 214 Phase 2 Phase 2 592 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 116 Phase 4 Phase 4 25 Not applicable Not applicable 225 Observational Observational 338

Trials per phase (log scale)

1 more section with rows

1,949 of the 1,949 trials are tagged with Carcinoma, Renal Cell itself; the rest are tagged with a narrower condition beneath it.

Get the Carcinoma, Renal Cell report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Carcinoma, Renal Cell trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 108

1990: 1 trials (Observational 1) 1991: 2 trials (Phase 3 1, Phase 2 1) 1992: 1 trials (Phase 3 1) 1993: 1 trials (Observational 1) 1994: 4 trials (Phase 3 1, Phase 2 1, Phase 1 2) 1995: 2 trials (Phase 2 2) 1996: 6 trials (Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 1997: 7 trials (Observational 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 1998: 15 trials (Phase 3 1, Phase 2 10, Phase 1/2 2, Phase 1 2) 1999: 15 trials (Not applicable 1, Phase 3 1, Phase 2 8, Phase 1 5) 2000: 28 trials (Observational 1, Phase 4 1, Phase 3 3, Phase 2 11, Phase 1/2 5, Phase 1 7) 2001: 28 trials (Observational 2, Not applicable 1, Phase 2 15, Phase 1/2 3, Phase 1 7) 2002: 24 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 14, Phase 1/2 4, Phase 1 3) 2003: 29 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 15, Phase 1/2 2, Phase 1 4) 2004: 50 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 8) 2005: 56 trials (Other 1, Observational 3, Not applicable 2, Phase 3 4, Phase 2 27, Phase 1/2 9, Phase 1 10) 2006: 64 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2 31, Phase 1/2 7, Phase 1 15) 2007: 74 trials (Observational 9, Not applicable 9, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 38, Phase 1/2 3, Phase 1 9) 2008: 84 trials (Observational 21, Not applicable 6, Phase 4 4, Phase 3 4, Phase 2 28, Phase 1/2 5, Phase 1 16) 2009: 62 trials (Observational 15, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 21, Phase 1/2 5, Phase 1 13) 2010: 64 trials (Observational 16, Not applicable 4, Phase 3 6, Phase 2 15, Phase 1/2 9, Phase 1 14) 2011: 58 trials (Observational 14, Not applicable 4, Phase 4 2, Phase 3 4, Phase 2 21, Phase 1/2 3, Phase 1 10) 2012: 68 trials (Other 1, Observational 10, Not applicable 10, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 18, Phase 1/2 4, Phase 1 16) 2013: 45 trials (Observational 7, Not applicable 10, Phase 3 1, Phase 2 12, Phase 1/2 4, Phase 1 11) 2014: 58 trials (Observational 12, Not applicable 13, Phase 3 1, Phase 2 12, Phase 1/2 7, Phase 1 13) 2015: 64 trials (Observational 12, Not applicable 10, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 12, Phase 1/2 8, Phase 1 18) 2016: 93 trials (Observational 17, Not applicable 9, Phase 4 1, Phase 3 5, Phase 2 23, Phase 1/2 14, Phase 1 24) 2017: 78 trials (Observational 9, Not applicable 7, Phase 4 1, Phase 3 9, Phase 2 24, Phase 1/2 15, Phase 1 13) 2018: 86 trials (Observational 21, Not applicable 8, Phase 3 3, Phase 2 23, Phase 1/2 13, Phase 1 18) 2019: 96 trials (Observational 31, Not applicable 10, Phase 4 1, Phase 3 7, Phase 2 20, Phase 1/2 7, Phase 1 20) 2020: 97 trials (Observational 21, Not applicable 11, Phase 3 2, Phase 2 23, Phase 1/2 9, Phase 1 31) 2021: 94 trials (Observational 20, Not applicable 13, Phase 3 8, Phase 2 15, Phase 1/2 16, Phase 1 22) 2022: 98 trials (Observational 26, Not applicable 18, Phase 3 3, Phase 2 20, Phase 1/2 7, Phase 1 24) 2023: 108 trials (Observational 16, Not applicable 18, Phase 3 5, Phase 2/3 1, Phase 2 24, Phase 1/2 16, Phase 1 28) 2024: 84 trials (Observational 16, Not applicable 15, Phase 4 1, Phase 3 4, Phase 2 16, Phase 1/2 12, Phase 1 20) 2025: 97 trials (Observational 19, Not applicable 18, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 25, Phase 1/2 10, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 89
2025 97
2024 84
2023 108
2022 98
2021 94
2020 97
2019 96
2018 86
2017 78

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 98 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 245 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 1,221 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Carcinoma, Renal Cell trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 426
Phase 1/2 214
Phase 2 592
Phase 2/3 6
Phase 3 116
Phase 4 25
Not applicable 225
Observational 338
Expanded access 7

How many Carcinoma, Renal Cell trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 54
Recruiting 263
Enrolling by invitation 6
Active, not recruiting 156
Completed 909

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Carcinoma, Renal Cell trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 116
Pfizer 72
Novartis Pharmaceuticals 35
Bristol-Myers Squibb 31
Bayer 29

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Carcinoma, Renal Cell? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
NIVOLUMAB 123
PEMBROLIZUMAB 115
Sorafenib 68
EVEROLIMUS 59
AXITINIB 57

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Sunitinib 4/2 126
Bevacizumab 1 63
Pazopanib Pill 55
Low-dose Aldesleukin (Proleukin®) 39
SQ Fludarabine 37

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Carcinoma, Renal Cell trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 915 125
Malignant neoplasm progression 851 39
Disease progression 791 48
Hypertension 742 97
Fatigue 703 128

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Carcinoma, Renal Cell? (1,350)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Annals of oncology : official journal of the European Society for Medical Oncology 2026 Yes
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Annals of oncology : official journal of the European Society for Medical Oncology 2026 Yes
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study. International journal of urology : official journal of the Japanese Urological Association 2026 Yes
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. European urology 2025 Yes
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800). Cancer 2025 Yes

Showing 5 of 1,350 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Renal cell carcinoma Point prevalence 1-5 / 10 000 Europe Not stated Unspecified
Renal cell carcinoma Annual incidence 1-9 / 100 000 Europe Not stated Exact
Renal cell carcinoma Point prevalence 1-5 / 10 000 Europe Not stated Exact
Renal cell carcinoma Annual incidence 1-9 / 100 000 Europe Not stated Exact
Renal cell carcinoma Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Renal cell carcinoma 217071 Exact Orphanet Rare Disease Ontology (ORDO)
Renal cell carcinoma 217071 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages